References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A,
et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J
Clin. 2021 May;71(3):209–49.
2. Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of
liver fibrosis and its clinical significance in nonalcoholic fatty liver
disease. Hepatol Res. 2022 Jun;52(6):497–507.
3. Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, et
al. Longitudinal association of magnetic resonance
elastography-associated liver stiffness with complications and
mortality. Aliment Pharmacol Ther. 2022 Feb;55(3):292–301.
4. Capuozzo M, Santorsola M, Landi L, Granata V, Perri F, Celotto V, et
al. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New
towards Precision Oncology. Int J Mol Sci. 2022 Dec;23(23):15124.
5. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for
intrahepatic cholangiocarcinoma. J Hepatol. 2020 Feb;72(2):353–63.
6. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A,
et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med. 2010 Apr;362(14):1273–81.
7. Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, et al.
Second-line chemotherapy in advanced biliary cancers: A retrospective,
multicenter analysis of outcomes. Cancer. 2019 Dec;125(24):4426–34.
8. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al.
Gemcitabine alone or in combination with cisplatin in patients with
advanced or metastatic cholangiocarcinomas or other biliary tract
tumours: a multicentre randomised phase II study - The UK ABC-01 Study.
Br J Cancer. 2009 Aug;101(4):621–7.
9. Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, et
al. A multicenter phase II study of S-1 for gemcitabine-refractory
biliary tract cancer. Cancer Chemother Pharmacol. 2013
May;71(5):1141–6.
10. Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, et al.
A retrospective study of S-1 monotherapy as second-line treatment for
patients with advanced biliary tract cancer. Jpn J Clin Oncol. 2012
Sep;42(9):800–6.
11. Ishido S, Tsuchiya K, Kano Y, Yasui Y, Takaura K, Uchihara N, et al.
Clinical Utility of Comprehensive Genomic Profiling in Patients with
Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2023
Jan;15(3):719.
12. Lin Q, Chen X, Qu L, Guo M, Wei H, Dai S, et al. Characterization of
the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Commun Chem. 2022 Aug;5(1):100.
13. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna
G, et al. Liquid versus tissue biopsy for detecting acquired resistance
and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019
Sep;25(9):1415–21.
14. Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et
al. Clinical utility of circulating tumor DNA sequencing in advanced
gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat
Med. 2020 Dec;26(12):1859–64.
15. Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D,
Pereira AAL, et al. Genomic Landscape of Cell-Free DNA in Patients with
Colorectal Cancer. Cancer Discov. 2018 Feb;8(2):164–73.
16. Esagian SM, Grigoriadou GΙ, Nikas IP, Boikou V, Sadow PM, Won JK, et
al. Comparison of liquid-based to tissue-based biopsy analysis by
targeted next generation sequencing in advanced non-small cell lung
cancer: a comprehensive systematic review. J Cancer Res Clin Oncol. 2020
Aug;146(8):2051–66.
17. Yoshinami T, Kagara N, Motooka D, Nakamura S, Miyake T, Tanei T, et
al. Detection of ctDNA with Personalized Molecular Barcode NGS and Its
Clinical Significance in Patients with Early Breast Cancer. Transl
Oncol. 2020 Aug;13(8):100787.
18. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J,
et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory
cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 2020
Jun;21(6):796–807.
19. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New
routes to targeted therapy of intrahepatic cholangiocarcinomas revealed
by next-generation sequencing. Oncologist. 2014 Mar;19(3):235–42.
20. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi
R, et al. Pemigatinib for previously treated, locally advanced or
metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2020 May;21(5):671–84.